Professional Media briefs

Elsevier's Skin & Allergy News Digital Network launched Product Zone, a targeted product and digital resource center designed to assist dermatologists, physicians and related healthcare professionals in making informed purchasing decisions. The microsite will feature videos, white papers, webcasts, case studies as well as more than 4,000 derm product, company and resource listings.

Wolters Kluwer Health's Ovid unit announced it has partnered with nine new premium publishers to deliver full-text content through its OvidSP search, discovery and management platform. Ovid, which offers customizable electronic research info for the medical, scientific and academic markets, works with over 150 publishers.

GlaxoSmithKline wrote a “Dear doctor” letter to recipients of a GSK-sponsored paid supplement hyping Avodart, Dow Jones Newswires reported. The  supplement ran in the May 2009 edition of the journal Urology and included clinical trials data on Avodart's prostate cancer-fighting abilities, for which the drug does not have FDA approval. In the letter, GSK North America head Dierdre Connelly conceded that the company had helped to develop content and select the authors of the supplement.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.